NCI What NCI did with the money: Sharpless boosts funding for RPGs, centers, SPOREs, NCTN, and NCORP June 29, 2018Vol.44 No.26By Matthew Bin Han Ong
Senate committee proposes $2 billion raise for NIH, signaling fourth good year in a row June 29, 2018Vol.44 No.26By Jordan Williams and Matthew Bin Han Ong
Drugs & Targets FDA approves Avastin in combination with chemotherapy for ovarian cancer June 15, 2018Vol.44 No.24
Drugs & Targets FDA approves Keytruda for previously treated patients with recurrent or metastatic cervical cancer whose tumors express PD-L1 June 15, 2018Vol.44 No.24
Drugs & Targets TESARO, Genentech to study Zejula with anti-PD-L1 agent, MEK inhibitor in ovarian cancer June 15, 2018Vol.44 No.24
Drugs & Targets FDA approves Venclexta with rituximab as a fixed duration treatment for CLL or SLL after one prior therapy June 15, 2018Vol.44 No.24
